Ontology highlight
ABSTRACT:
SUBMITTER: Jamieson SM
PROVIDER: S-EPMC6141174 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature
Jamieson Stephen Mf SM Tsai Peter P Kondratyev Maria K MK Budhani Pratha P Liu Arthur A Senzer Neil N NN Chiorean E Gabriela EG Jalal Shadia I SI Nemunaitis John J JJ Kee Dennis D Shome Avik A Wong Way W WW Li Dan D Poonawala-Lohani Nooriyah N Kakadia Purvi M PM Knowlton Nicholas S NS Lynch Courtney Rh CR Hong Cho R CR Lee Tet Woo TW Grénman Reidar A RA Caporiccio Laura L McKee Trevor D TD Zaidi Mark M Butt Sehrish S Macann Andrew Mj AM McIvor Nicholas P NP Chaplin John M JM Hicks Kevin O KO Bohlander Stefan K SK Wouters Bradly G BG Hart Charles P CP Print Cristin G CG Wilson William R WR Curran Michael A MA Hunter Francis W FW
JCI insight 20180823 16
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines an ...[more]